Showing 3931-3940 of 4165 results for "".
- Lineage Cell Therapeutics Presents Additional Interim Data on OpRegen for Dry AMD With Geographic Atrophyhttps://modernod.com/news/lineage-cell-therapeutics-presents-additional-interim-data-on-opregen-for-dry-amd-with-geographic-atrophy/2479007/Lineage Cell Therapeutics announced new positive interim results from its ongoing, 24-patient phase 1/2a clinical study of its lead product candidate, OpRegen. OpRegen is an investigational cell therapy consisting of allogeneic retinal pigment epithelium (RPE) cells administered to the subretinal
- Judy F. Gordon, DVM, Founder of ClinReg Consulting Services, Retireshttps://modernod.com/news/judy-f-gordon-dvm-founder-of-clinreg-consulting-services-retires/2479004/Medical device and pharmaceutical consulting company ClinReg Consulting Services announced the retirement of its founder and president, Judy F. Gordon, DVM. Dr. Gordon has worked in the clinical and regulatory industry for more than 35 years, beginning with her career in the pharmaceutical
- Nicox’s NCX 470 Mont Blanc Phase 3 Glaucoma Trial Reaches 50% Enrollment Milestonehttps://modernod.com/news/nicoxs-ncx-470-mont-blanc-phase-3-glaucoma-trial-reaches-50-enrollment-milestone/2478999/Nicox announced that 50% of patients in the Mont Blanc NCX 470 phase 3 glaucoma clinical trial have now been randomized out of a target of 670, with topline results currently on track to be announced during Q2 2022. “We have been successful in maintaining a good recruitment rate in the Mon
- New Open Access Ophthalmology Journal Now Livehttps://modernod.com/news/new-open-access-ophthalmology-journal-now-live/2478998/Ophthalmology Science—the American Academy of Ophthalmology’s first open access journal—is now live and accepting submissions. Ophthalmology Science is an online open access journal focused on publishing preclinical development, phase 1 and 2 clinical trials, laboratory
- New Study Finds Significant Improvements in DED Following Use of Eye Eco Tranquileyes XL and Tranquilvibes Hydrating Maskshttps://modernod.com/news/new-study-finds-significant-improvements-in-ded-following-use-of-eye-eco-tranquileyes-xl-and-tranquilvibes-hydrating-masks/2478984/Eye Eco announced results of a study validating the clinical benefits of its moist heat masks, Tranquilvibes and Tranquileyes XL, for improving the signs and symptoms of dry eye disease caused by meibomian gland dysfunction (MGD). Patients who used the masks to treat tired, dry, gritty, inflamed
- New iCare HOME2 Self-Tonometer Enables Eye Pressure Measurement by Glaucoma Patientshttps://modernod.com/news/new-icare-home2-self-tonometer-enables-accurate-eye-pressure-measurement-by-glaucoma-patients/2478976/Icare Finland is launching their next generation self-tonometer, the iCare HOME2. iCare HOME2 provides ease of use and accuracy in monitoring real-world IOP behavior outside of the doctor’s office and clinical hours, supporting glaucoma management, according to a company news release
- EyeYon Medical Raises $25 million in Series C to Transform Corneal Carehttps://modernod.com/news/eyeyon-medical-raises-25-million-in-series-c-to-transform-corneal-care/2478969/EyeYon Medical announced the completion of a $25 million in a Series C funding, which will be used to expand the clinical trials of EyeYon Medical’s flagship product, EndoArt. EndoArt is the first synthetic implant that enables doctors to treat chronic corneal edema with a minimally invasi
- Ocuphire Announces Publication of MIRA-1 Phase 2b Results Demonstrating Reduction of Pharmacologically Induced Mydriasis by Nyxolhttps://modernod.com/news/ocuphire-announces-publication-of-mira-1-phase-2b-results-demonstrating-reduction-of-pharmacologically-induced-mydriasis-by-nyxol/2478940/Ocuphire Pharma announced that the results from the MIRA-1 (NCT04024891) phase 2b clinical trial evaluating the safety and efficacy of Nyxol in the reversal of mydriasis have been published in Optometry and Visual Science. The article will appear in the print edition and is available on-
- Retinal Therapeutics Development Company Oxular Completes $37 Million (£27 million) Financinghttps://modernod.com/news/retinal-therapeutics-development-company-oxular-completes-37-million-27-million-financing/2478922/Oxular announced that it has completed a $37 million (£27 million) to fund planned further clinical development of its lead asset, OXU-001, for the treatment of diabetic macular edema (DME), as well as accelerating development of its early-product pipeline. The financing was led by Forbion
- Remembering Ophthalmic Industry Executive George Marcellinohttps://modernod.com/news/remembering-george-marcellino-vice-president-of-marketing-and-clinical-affairs/2478916/Ophthalmic industry executive George Marcellino, PhD, whose work lead to the development of several new technologies and medical devices, died on February 10, 2021. Most recently, Dr. Marcellino served as vice president of clinical affairs and marketing at Iridex. On its website, Iridex posted th